Allergan Presents Data From Eleven Abstracts At The 2019 American Society for Dermatologic Surgery (ASDS) in Chicago
DUBLIN, Oct. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, IL October 24-27 2019.
The meeting will be held at the Hyatt Regency Chicago and the scheduled times (noted in local Central Time) for the Allergan presentations are as follows:
OnabotulinumtoxinA 24 to 96 U Is Well Tolerated and Safe for Treatment of Masseter Muscle Prominence: Results of a Phase 2 Study
Chin Augmentation with the Hyaluronic Acid Injectable Filler, VYC-20L
Safety and Effectivness of Hyaluronic Acid Injectable Filler, VYC-20L, Using a Cannula for Cheek Augmentation: Results from a Multicenter, Randomized, Single-Blind, Controlled Study
The Beauty Image Assessment Study: Perspectives on Facial Aesthetics and Treatment
Change from Baseline in Caliper Measurements of Submental Fat Thickness and Probability of Response to Treatment: Post Hoc Analyses of Pooled Data from the ATX-101 Pivotal Trials
Clinical Benefit of ATX-101 in Treatment Nonresponders in Reporting Treatment Satisfaction: Post Hoc Analysis of Pivotal Trials in Patients with Moderate to Severe Submental Fat
Submental Fat Reduction Using Sequential Treatment with Cryolipolysis and ATX-101
Greater Biological Activity and Non-Interchangeability of BOTOX® Compared with Vacuum-Dried NABOTA®
Clinical Efficacy of a Novel Topical Treatment for Periocular Dark Circles
Post Hoc Analysis of MRI Data from Non-responders in the Phase 3, Multicenter, Double-blind, Randomized Placebo-Controlled REFINE-1 and REFINE-2 Trials
OnabotulinimtoxinA for Treatment of Masseter Muscle Prominence: Secondary Results from a Phase 2 Dose Escalation Study
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.
With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan’s Quarterly Report on Form 10-Q for the period ended June 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Manisha Narasimhan, PhD
View original content to download multimedia: http://www.prnewswire.com/news-releases/allergan-presents-data-from-eleven-abstracts-at-the-2019-american-society-for-dermatologic-surgery-asds-in-chicago-300943617.html
SOURCE Allergan plc